FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
The purpose of the study is to investigate the efficacy and safety for steroid non-resistant
 MG patients in a double blind, placebo controlled study.
Inclusion Criteria:

 -  Clinically diagnosed as myasthenia gravis

 -  Those whose MG symptoms are well-controlled by the treatment with prednisone

 -  Steroid non-refractory Myasthenia Gravis: ≧20mg and ≦40mg / alternate day of steroid
 dose required to maintain

 Exclusion Criteria:

 -  Those who have thymoma or the history of thymoma (Masaoka stage III or IV)

 -  Patients who received steroid pulse therapy, plasma exchange therapy, globulin therapy
 or radiation therapy within 12 weeks prior to the initiation of test drug

 -  Patients who started the immunosuppressant therapy or increased the dose of
 immunosuppressant within 12 weeks prior to the initiation of test drug.

 -  Patients who had undergone thymectomy within 24 weeks prior to the initiation of test
 drug.

 -  Pancreatitis or diabetes

 -  Serum creatinine≦1.5mg/dL